Len Schleifer (left) and George Yancopoulos, Regeneron (Vimeo)
Eyes on hemophilia prize, Regeneron adds a $100M wager on joint development campaign with Intellia
When George Yancopoulos first signed up Intellia to be its CRISPR/Cas9 partner on gene editing projects 4 years ago, the …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
